Young Adults with Digestive and Neuroendocrine Cancers
Part of Cancer clinical trials.
This trial studies treatments for young adults (ages 18-39) with cancers of the digestive system or neuroendocrine tumors. It aims to find better ways to help this age group, no matter the cancer stage or grade.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed between ages 18 and 39.
- You have a type of cancer that starts in the digestive tract (such as esophagus, stomach, pancreas, liver, bowel, or anus) or a neuroendocrine tumor (a rare, slow-growing tumor) from the digestive system, lungs, or thymus.
- Your cancer can be any stage or grade (how aggressive it is).
- Your diagnosis was made within the last 2 years, or you are willing to have a biopsy to confirm the type of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at epigenomic markers in different types of neuroendocrine tumors and cancers to find better ways to diagnose and treat them. It may help if you have a neuroendocrine tumor or certain other gastrointestinal cancers that can be surgically removed or biopsied.
This is a registry study that collects medical information from adults with neuroendocrine tumors (NETs) that start in the digestive organs. It helps researchers understand these cancers better and may support future studies.
This study observes people aged 18-49 with a new gastrointestinal cancer (colorectal, stomach/esophageal, or pancreatic) to learn how their lifestyle habits and tumor characteristics affect their health. By participating, you help researchers understand why these cancers occur in younger adults.
This study is a registry, meaning it collects information about young adults diagnosed with pancreatic cancer. It may help researchers better understand this cancer in younger people and improve future care.
This study looks at how tumor and patient factors affect treatment response in well-differentiated GEP-NENs (neuroendocrine tumors of the digestive system). It may help doctors understand which treatments work best for people like you.
This study looks at whether chemotherapy given before surgery improves how long patients live without the cancer coming back. It’s aimed at people with localized, poorly differentiated digestive neuroendocrine carcinoma with a higher growth rate marker.
Hear when a new Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.